Podcast: How Sandoz plans to harness its “golden decade”
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap…
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap…
Despite the region’s reputation as a thriving hub of innovation, Nordic biotechs are having a hard time funding the jump to commercialisation, and experts say there is a risk the…
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to fame in the innovative medicines space and the advent of…
It's conference season again. In this episode, the healthcare team rounds up the latest readouts and emerging themes from two recent events: the European Society of Cardiology (ESC) Congress and…
Osaka has the science. Now it needs to build the companies, capital and global reach to turn that science into an industry. Kansai - the Japanese region encompassing Osaka, Kyoto…
The FDA’s acceptance of several untested peptides for human use has left one drug innovator calling for a greater clarity of understanding around a drug class that is widely known…
Filling a Keytruda-sized sales void was always going to be challenging, but Merck & Co (MSD) may have crafted a medicine that can go some way in maintaining healthy revenue…